Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00266669
Status:
COMPLETED
Last Update Posted:
2007-08-08
First Post:
2005-12-15
Brief Title:
Phase III Study of Topical Gel for Treatment and Prevention of Raynauds Phenomenon
Sponsor:
MediQuest Therapeutics
Organization:
MediQuest Therapeutics
Study Overview
Official Title:
Phase III in-Life Study of a Topical Gel Formulation of Nitroglycerin MQX-503 and Matching Placebo Gel in the Treatment and Prevention of Raynauds Phenomenon
Status:
COMPLETED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin in comparison to a matching placebo for patients with moderate to severe primary Raynauds phenomenon or patients with Raynauds phenomenon secondary to autoimmune diseases such as scleroderma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MQX-503 In-Life | None | None | None |